Evolving Treatment Choices and New Guidance

CME

Heart Failure: Evolving Treatment Choices and New Guidance

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: October 24, 2022

Expiration: October 23, 2023

Pretest

Progress
1 2
Course Completed
1.

How confident are you in your ability to develop individualized management plans for patients with heart failure?

2.

Diane is a 60-year-old white woman just diagnosed with stage C HFrEF. She has HTN but not diabetes. Her BP is 104/65 mm Hg, heart rate is 65 bpm in sinus rhythm, potassium is 5.3 mEq/L and eGFR is 65 mL/min/1.73 m2. You start her on an evidence-based β-blocker, sacubitril/valsartan, and prescribe a diuretic for as needed use (she is not volume overloaded).

To provide optimal evidence-based care per the 2021 ACC guidelines, would you add any other medication?

3.

A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, found SGLT2is to reduce CV death or HHF by what percentage?

4.

In the AFFIRM-HF trial, patients who received IV ferric carboxymaltose had a relative risk for readmission for HF and/or decrease death from CV causes compared with placebo of:

5.

Jim is a 65-year-old man who has had HFrEF for 3 years. He is employed full-time as a vice president in his company. He continues to have symptoms and admits to only intermittent compliance with his medication.

Per the 2022 updated ACC guidance, screening for which of the following might be the most useful in helping him overcome his barrier to self-care?